- Home
- CSTL
as of 03-20-2026 3:56pm EST
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FRIENDSWOOD |
| Market Cap: | 806.3M | IPO Year: | 2019 |
| Target Price: | $47.17 | AVG Volume (30 days): | 398.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | -0.83 | EPS Growth: | -233.87 |
| 52 Week Low/High: | $14.59 - $44.28 | Next Earning Date: | 05-04-2026 |
| Revenue: | $344,229,000 | Revenue Growth: | 3.66% |
| Revenue Growth (this year): | 2.42% | Revenue Growth (next year): | 12.69% |
| P/E Ratio: | -30.96 | Index: | N/A |
| Free Cash Flow: | 28.3M | FCF Growth: | -22.48% |
AI-Powered CSTL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Castle Biosciences Inc. (CSTL)
Pres. & Chief Exec. Officer
Avg Cost/Share
$25.39
Shares
650
Total Value
$16,503.50
Owned After
21,479
SEC Form 4
Pres. & Chief Exec. Officer
Avg Cost/Share
$25.93
Shares
18,650
Total Value
$483,594.50
Owned After
21,479
SEC Form 4
Pres. & Chief Exec. Officer
Avg Cost/Share
$26.32
Shares
17,575
Total Value
$456,407.52
Owned After
21,479
Pres. & Chief Exec. Officer
Avg Cost/Share
$25.45
Shares
13,204
Total Value
$336,002.19
Owned After
21,479
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$25.24
Shares
20,863
Total Value
$526,582.12
Owned After
86,825
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$27.98
Shares
6,001
Total Value
$167,907.98
Owned After
60,085
SEC Form 4
Director
Avg Cost/Share
$28.48
Shares
7,403
Total Value
$210,727.17
Owned After
19,309
Chief Financial Officer
Avg Cost/Share
$27.56
Shares
7,000
Total Value
$192,073.00
Owned After
60,085
Pres. & Chief Exec. Officer
Avg Cost/Share
$38.22
Shares
817
Total Value
$31,035.32
Owned After
21,479
Pres. & Chief Exec. Officer
Avg Cost/Share
$39.91
Shares
3,200
Total Value
$127,721.60
Owned After
21,479
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Mar 18, 2026 | Sell | $25.39 | 650 | $16,503.50 | 21,479 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Mar 17, 2026 | Sell | $25.93 | 18,650 | $483,594.50 | 21,479 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Mar 16, 2026 | Sell | $26.32 | 17,575 | $456,407.52 | 21,479 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Mar 13, 2026 | Sell | $25.45 | 13,204 | $336,002.19 | 21,479 | |
| Juvenal Tobin W | CSTL | Chief Commercial Officer | Mar 12, 2026 | Sell | $25.24 | 20,863 | $526,582.12 | 86,825 | |
| Stokes Frank | CSTL | Chief Financial Officer | Mar 5, 2026 | Sell | $27.98 | 6,001 | $167,907.98 | 60,085 | |
| Cole G Bradley | CSTL | Director | Mar 5, 2026 | Sell | $28.48 | 7,403 | $210,727.17 | 19,309 | |
| Stokes Frank | CSTL | Chief Financial Officer | Mar 3, 2026 | Sell | $27.56 | 7,000 | $192,073.00 | 60,085 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Feb 4, 2026 | Sell | $38.22 | 817 | $31,035.32 | 21,479 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Feb 3, 2026 | Sell | $39.91 | 3,200 | $127,721.60 | 21,479 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 26, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYFeb 26, 2026 · 100% conf.
1D
+7.09%
$34.14
Act: -7.43%
5D
+12.36%
$35.82
Act: -12.45%
20D
+11.73%
$35.62
cstl-202602260001447362FALSE00014473622026-02-262026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2026
Castle Biosciences, Inc. (Exact name of registrant as specified in its charter)
Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
1500 W. Parkwood Ave, Suite 400 Friendswood, Texas 77546 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (866) 788-9007
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per shareCSTL The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 26, 2026, Castle Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information contained or incorporated in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 7.01 Regulation FD Disclosure.
On February 26, 2026, the Company made available the slide presentation attached hereto as Exhibit 99.2. Information from these slide presentations may also be used by the management of the Company in future meetings regarding the Company.
The information contained or incorporated in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit NumberDescription 99.1Press release issued February 26, 2026.
99.2Slide presentation.
104Inline XBRL for the cover page of this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CASTLE BIOSCIENCES, INC.
By:/s/ Frank Stokes Frank Stokes Chief Financial Officer Date: February 26, 2026
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 13, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYJan 13, 2026 · 100% conf.
1D
+7.09%
$34.14
Act: -7.43%
5D
+12.36%
$35.82
Act: -12.45%
20D
+11.73%
$35.62
cstl-202601110001447362FALSE00014473622026-01-112026-01-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 11, 2026
Castle Biosciences, Inc. (Exact name of registrant as specified in its charter)
Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
505 S. Friendswood Drive, Suite 401 Friendswood, Texas 77546 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (866) 788-9007
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.001 par value per shareCSTLThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 11, 2026, Castle Biosciences, Inc. (the “Company”) issued a press release announcing certain preliminary performance results for the fourth quarter of 2025 and for the year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information contained or incorporated in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 7.01 Regulation FD Disclosure.
On January 11, 2026, the Company made available the slide presentation attached hereto as Exhibit 99.2. Information from this slide presentation may also be used by the management of the Company in future meetings regarding the Company.
The information contained or incorporated in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit NumberDescription 99.1Press release issued January 11, 2026.
99.2Slide presentation.
104Inline XBRL for the cover page of this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CASTLE BIOSCIENCES, INC.
By:/s/ Frank Stokes Frank Stokes Chief Financial Officer Date: January 11, 2026
2025 Q3 Q3 2025 Earnings
8-K Nov 3, 2025
Q3 2025 Earnings
8-KNov 3, 2025
cstl-202511030001447362FALSE00014473622025-11-032025-11-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 3, 2025
Castle Biosciences, Inc. (Exact name of registrant as specified in its charter)
Delaware 001-38984 77-0701774 (state or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
505 S. Friendswood Drive, Suite 401 Friendswood, Texas 77546 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (866) 788-9007
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per shareCSTL The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 3, 2025, Castle Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information contained or incorporated in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 7.01 Regulation FD Disclosure.
On November 3, 2025, the Company made available the slide presentation attached hereto as Exhibit 99.2. Information from this slide presentation may also be used by the management of the Company in future meetings regarding the Company.
The information contained or incorporated in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit NumberDescription 99.1Press release issued November 3, 2025.
99.2Slide presentation.
104Inline XBRL for the cover page of this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CASTLE BIOSCIENCES, INC.
By:/s/ Frank Stokes Frank Stokes Chief Financial Officer Date: November 3, 2025
Compare CSTL vs Leading Stocks
See how CSTL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CSTL Castle Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.